Reason for request
Inclusion on list of products reimbursed by National Insurance and for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of FIRMAGON is substantial. |
Clinical Added Value
| no clinical added value |
In the context of the current strategy for treatment of advanced prostate cancer, with a combination of a Gn-RH analogue and an antiandrogen in the first month of treatment, FIRMAGON provides no improvement in actual benefit (IAB level V). |
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
1hsAZEpEaeJqVerG
